Ascentage Pharma Reports Promising ASCO 2026 Data for Three Lead Oncology Drugs
Event summary
- Ascentage Pharma presented six abstracts at ASCO 2026, with three selected for rapid oral presentations and three for poster presentations.
- Olverembatinib (HQP1351) showed promising results in combination with blinatumomab for relapsed/refractory Ph+ BCP-ALL and CML-LBP, with four out of five patients achieving complete response.
- Alrizomadlin (APG-115) demonstrated preliminary antitumor activity in pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) and other soft-tissue sarcomas (STSs).
- The company is conducting multiple global Phase III trials, including the POLARIS-2 trial for olverembatinib and the GLORA trial for lisaftoclax.
The big picture
Ascentage Pharma's presentation at ASCO 2026 underscores its strategic focus on developing novel therapies for unmet medical needs in cancer. The company's lead drug candidates, olverembatinib, lisaftoclax, and alrizomadlin, are being evaluated in multiple clinical trials, positioning Ascentage Pharma as a key player in the global oncology market. The ongoing Phase III trials and partnerships with leading biotechnology and pharmaceutical companies further strengthen its competitive position.
What we're watching
- Clinical Efficacy
- How the combination of olverembatinib with blinatumomab will impact treatment paradigms for relapsed/refractory Ph+ BCP-ALL and CML-LBP.
- Regulatory Pathways
- Whether the promising data from ASCO 2026 will accelerate the approval process for olverembatinib, lisaftoclax, and alrizomadlin in key markets.
- Market Positioning
- The pace at which Ascentage Pharma can establish itself as a leader in the oncology space, given the competitive landscape and the need for differentiated therapies.
Related topics